Bristol Myers Squibb Company $BMY Position Raised by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. grew its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 2.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 5,259,966 shares of the biopharmaceutical company’s stock after acquiring an additional 114,313 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned about 0.26% of Bristol Myers Squibb worth $237,224,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Gateway Investment Advisers LLC lifted its position in Bristol Myers Squibb by 10.0% in the 3rd quarter. Gateway Investment Advisers LLC now owns 113,457 shares of the biopharmaceutical company’s stock worth $5,117,000 after buying an additional 10,284 shares in the last quarter. Commonwealth Retirement Investments LLC increased its stake in shares of Bristol Myers Squibb by 24.6% in the second quarter. Commonwealth Retirement Investments LLC now owns 59,183 shares of the biopharmaceutical company’s stock worth $2,740,000 after acquiring an additional 11,690 shares during the last quarter. CWA Asset Management Group LLC increased its stake in shares of Bristol Myers Squibb by 25.9% in the third quarter. CWA Asset Management Group LLC now owns 150,359 shares of the biopharmaceutical company’s stock worth $6,781,000 after acquiring an additional 30,909 shares during the last quarter. Norges Bank acquired a new stake in Bristol Myers Squibb during the second quarter valued at $1,554,154,000. Finally, Wealth Quarterback LLC boosted its position in Bristol Myers Squibb by 42.6% during the second quarter. Wealth Quarterback LLC now owns 25,443 shares of the biopharmaceutical company’s stock valued at $1,178,000 after purchasing an additional 7,603 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

BMY has been the topic of several recent research reports. Wells Fargo & Company raised their price objective on shares of Bristol Myers Squibb from $53.00 to $55.00 and gave the company an “equal weight” rating in a research report on Wednesday, December 10th. Citigroup restated a “neutral” rating and set a $53.00 price target (up previously from $45.00) on shares of Bristol Myers Squibb in a report on Wednesday, January 7th. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Bank of America raised shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and increased their target price for the stock from $52.00 to $61.00 in a research report on Monday, December 15th. Finally, UBS Group raised Bristol Myers Squibb from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $46.00 to $65.00 in a research report on Wednesday, January 7th. Six analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Bristol Myers Squibb currently has a consensus rating of “Hold” and a consensus price target of $56.62.

Bristol Myers Squibb Stock Performance

NYSE:BMY opened at $55.78 on Tuesday. The firm has a market capitalization of $113.55 billion, a PE ratio of 18.84, a PEG ratio of 9.25 and a beta of 0.29. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $63.33. The company has a current ratio of 1.27, a quick ratio of 1.17 and a debt-to-equity ratio of 2.39. The firm’s fifty day simple moving average is $51.12 and its 200 day simple moving average is $47.87.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.52 by $0.11. The company had revenue of $12.22 billion during the quarter, compared to analysts’ expectations of $11.75 billion. Bristol Myers Squibb had a net margin of 12.57% and a return on equity of 76.53%. The business’s quarterly revenue was up 2.8% compared to the same quarter last year. During the same period in the prior year, the company earned $1.80 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. On average, sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.5%. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date is Friday, January 2nd. Bristol Myers Squibb’s dividend payout ratio is presently 85.14%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.